Research
Hormonal
Adiponectin levels increase significantly post-semaglutide add-on therapy, with the greatest increase in the obesity group (+3.70 μg/mL).
Increased adiponectin levels with semaglutide may enhance metabolic health in diabetic patients.
StrongSupportsmedium confidence
Adiponectin levels increased significantly post-semaglutide add-on therapy (p < 0.05).
Why this rating
The study design supports the reliability of the findings.
Source
Effect of Semaglutide Add-on to Metformin on Visceral Adiposity Index and Markers of Visceral Adipose Tissue Activity in Type 2 Diabetic Patients
Abid Shaheer et al. · Biomedical & Pharmacology Journal · 2025
DOI 10.13005/bpj/3192
other · n=90Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide add-on to metformin significantly decreases the Visceral Adiposity Index (VAI) in type 2 diabetic patients, with the greatest reduction in the obesity group (-0.70).Strong
- Leptin levels significantly decline following semaglutide treatment, particularly in the obesity group (-5.10 ng/mL).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →